title: Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MS(n), and LC-HR-MS/MS.
abstract: 25I-NBOMe, a new psychoactive substance, is a potent 5-HT2A receptor agonist with strong hallucinogenic potential. Recently, it was involved in several fatal and non-fatal intoxication cases. The aim of the present work was to study its phase I and II metabolism and its detectability in urine screening approaches. After application of 25I-NBOMe to male Wistar rats, urine was collected over 24 h. The phase I and II metabolites were identified by LC-HR-MS/MS in urine after suitable workup. For the detectability studies, standard urine screening approaches (SUSA) by GC-MS, LC-MS(n), and LC-HR-MS/MS were applied to rat and also to authentic human urine samples submitted for toxicological analysis. Finally, an initial CYP activity screening was performed to identify CYP isoenzymes involved in the major metabolic steps. 25I-NBOMe was mainly metabolized by O-demethylation, O,O-bis-demethylation, hydroxylation, and combinations of these reactions as well as by glucuronidation and sulfation of the main phase I metabolites. All in all, 68 metabolites could be identified. Intake of 25I-NBOMe was detectable mainly via its metabolites by both LC-MS approaches, but not by the GC-MS SUSA. Initial CYP activity screening revealed the involvement of CYP1A2 and CYP3A4 in hydroxylation and CYP2C9 and CYP2C19 in O-demethylation. The presented study demonstrated that 25I-NBOMe was extensively metabolized and could be detected only by the LC-MS screening approaches. Since CYP2C9 and CYP3A4 are involved in initial metabolic steps, drug-drug interactions might occur in certain constellations.
authors.affiliation: Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Saarland University, 66421, Homburg, Saar, Germany.
authors.forename: Achim T
authors.initials: AT
authors.lastname: Caspar
authors.forename: Andreas G
authors.initials: AG
authors.lastname: Helfer
authors.forename: Julian A
authors.initials: JA
authors.lastname: Michely
authors.forename: Volker
authors.initials: V
authors.lastname: Auwärter
authors.forename: Simon D
authors.initials: SD
authors.lastname: Brandt
authors.forename: Markus R
authors.initials: MR
authors.lastname: Meyer
authors.forename: Hans H
authors.initials: HH
authors.lastname: Maurer
mesh_terms: D000818:Animals; D002853:Chromatography, Liquid / Q000379:methods; D015198:Designer Drugs / Q000032:analysis* / Q000633:toxicity; D004118:Dimethoxyphenylethylamine / Q000031:analogs & derivatives* / Q000633:toxicity / Q000652:urine; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods*; D006801:Humans; D008297:Male; D011619:Psychotropic Drugs / Q000652:urine*; D051381:Rats; D017208:Rats, Wistar; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D015813:Substance Abuse Detection / Q000379:methods*; D053719:Tandem Mass Spectrometry / Q000379:methods; D018675:Toxicity Tests / Q000379:methods; D016482:Urinalysis / Q000379:methods*
chemical_list: D015198:Designer Drugs; D004118:Dimethoxyphenylethylamine; D011619:Psychotropic Drugs; C554181:2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine